Jarid2-depleted cells show enhanced contribution to hematopoietic progenitors and mature cell lineages. (A) Relative contribution (mean + SD) of FL cells transduced with shRNA-NS (white), shRNA-Suz12 (hatched), shRNA-Jarid2.1 (dark gray), or shRNA-Jarid2.2 (light gray) to HSPCs at 6 weeks posttransplant. Thirteen to 16 recipients per shRNA from 3 independent cohorts. (B) Relative contribution of transduced cells to the BM (HSPCs: Lin^–cKit⁺Sca1⁺, myeloid progenitors [Prog]: Lin^–cKit⁺Sca1^–, mature [Mat] myeloid cells: Mac1⁺Gr1⁺), spleen (B220⁺/CD19⁺ B cells), and thymus (CD4⁺ single positive thymocytes) at 16 weeks posttransplant. Recipients are from 7 independent cohorts. (C) Representative fluorescence-activated cell sorter plots showing gating strategy to identify HSPC subpopulations using signaling lymphocytic activation molecule markers. LT-HSC: CD48^–CD150⁺, ST-HSC: CD48⁺CD150⁺, and MPP: CD48⁺CD150⁺. (D) Relative contribution (mean + SD) of transduced cells to HSPC subpopulations at 16 weeks posttransplant. Recipients are from 3 independent cohorts. (E) Relative contribution (mean + SD) of transduced cells to the BM at 16 weeks posttransplant. Secondary recipients are from 3 independent cohorts. (F) Peripheral blood platelet counts for secondary recipients at 6 and 10 weeks posttransplant. *P < .05, **P < .01, ***P < .001, and ****P < .0001 were calculated by using a two-way ANOVA with multiple comparisons in GraphPad Prism5 on logit-transformed data.